about
Physiologically Based Pharmacokinetic Modelling to Inform Development of Intramuscular Long-Acting Nanoformulations for HIV.Applications of physiologically based pharmacokinetic modeling for the optimization of anti-infective therapies.Simulating Intestinal Transporter and Enzyme Activity in a Physiologically Based Pharmacokinetic Model for Tenofovir Disoproxil Fumarate.Use of a physiologically based pharmacokinetic model to simulate drug-drug interactions between antineoplastic and antiretroviral drugs.Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions with Efavirenz Involving Simultaneous Inducing and Inhibitory Effects on Cytochromes.Physiologically based pharmacokinetic modelling prediction of the effects of dose adjustment in drug-drug interactions between levonorgestrel contraceptive implants and efavirenz-based ART.A physiologically based pharmacokinetic model to predict the superparamagnetic iron oxide nanoparticles (SPIONs) accumulation in vivoPhysiologically based pharmacokinetic models for the optimization of antiretroviral therapy: recent progress and future perspectiveDerivation of CYP3A4 and CYP2B6 degradation rate constants in primary human hepatocytes: A siRNA-silencing-based approachModelling the long-acting administration of anti-tuberculosis agents using PBPK: a proof of concept studyPredicting Drug-Drug Interactions Between Rifampicin and Long-Acting Cabotegravir and Rilpivirine Using Physiologically Based Pharmacokinetic ModelingPrediction of dolutegravir pharmacokinetics and dose optimization in neonates via physiologically based pharmacokinetic (PBPK) modellingPrioritisation of potential anti-SARS-CoV-2 drug repurposing opportunities based on ability to achieve adequate target site concentrations derived from their established human pharmacokineticsDose prediction for repurposing nitazoxanide in SARS-CoV-2 treatment or chemoprophylaxisModelling of Systemic versus Pulmonary Chloroquine Exposure in Man for COVID-19 Dose Selection
P50
Q35668556-AAF769A3-FCAE-4BDE-BDC1-B2D46D209734Q38420688-1BE30A79-5F2B-4287-85B6-7770E37AC2BDQ38833637-BF311738-DD00-4795-9A62-AEF01BBED5CEQ39080596-86729ADC-F689-40D1-9898-C6E5C30D3246Q39418438-8E0EE72F-3AE0-498C-9BFC-C2B9D1E60718Q48524975-DA5C5409-70DB-4053-A3EE-422182C41DADQ58073417-07B23074-34ED-4377-B661-7F70984ACA5AQ58073610-4CB29D09-1F14-47DD-A189-B76D94F5A713Q89157091-96190D9A-B30B-436C-9379-DADC6C8E261BQ89506293-E641C077-EE5E-434F-9525-B0B31D13C2E8Q90637197-177E4312-6301-4900-B2D6-4174C5E792D5Q92147200-E50A1BEA-D924-442E-8CA6-3A661D1902A5Q95601629-BEC1E26B-6DEE-4C39-8F6C-3A682C924FB1Q95614621-8B325D8D-1D9F-4264-9954-9CF2336B8B9DQ95616574-A18E9CD1-133E-40C1-B1B6-FC4A14AD4B30
P50
description
researcher ORCID ID = 0000-0002-6015-5712
@en
wetenschapper
@nl
name
Rajith Kumar Reddy Rajoli
@ast
Rajith Kumar Reddy Rajoli
@en
Rajith Kumar Reddy Rajoli
@es
Rajith Kumar Reddy Rajoli
@nl
type
label
Rajith Kumar Reddy Rajoli
@ast
Rajith Kumar Reddy Rajoli
@en
Rajith Kumar Reddy Rajoli
@es
Rajith Kumar Reddy Rajoli
@nl
prefLabel
Rajith Kumar Reddy Rajoli
@ast
Rajith Kumar Reddy Rajoli
@en
Rajith Kumar Reddy Rajoli
@es
Rajith Kumar Reddy Rajoli
@nl
P106
P31
P496
0000-0002-6015-5712